LZLitao Zhang

Litao Zhang

*This is an algorithmically generated author record based on publicly available information.

Litao Zhang has a total of 157 co-authors. Here are the top co-authors by number of shared publications:

  • Peng Cao

    Department of Dermatology, Tianjin lnstitute of lntegrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China

    5 shared publications
  • An-Kang Gu

    From the Department of Pathology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China

    3 shared publications
  • Ankang Gu

    Department of Pathology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China

    3 shared publications
  • Cunhao Shan

    Graduate School, Tianjin University of Traditional Chinese Medicine

    3 shared publications
  • Dongyun Lei

    Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin 300120, China

    3 shared publications
  • Junling Zhang

    Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin 300120, China

    3 shared publications

Latest Publications

  • Open Access

    Bruton Tyrosine Kinase Inhibitors in Immune-Mediated Skin Diseases: Current Evidence and Future Directions

    by Zihan Wang, Junchen He, Ting Zhang, Jiayu Peng, Lulu Xie, Bingrun Li, Cunhao Shan, Litao Zhang, Zuotao Zhao

    Bruton tyrosine kinase (BTK) is a central signaling molecule that links the B-cell receptor (BCR), Fc receptors, and Toll-like receptors (TLRs). By coordinating signaling in B cells, mast cells, macrophages, and other immune cells, BTK occupies an important position in cutaneous immune responses. BTK inhibitors (BTKis) can inhibit B-cell and Fc-receptor-dependent effector-cell signaling, providing a mechanistic rationale for several immune-mediated skin diseases. However, these cellular effects should not be equated with suppression of established autoantibody production or durable disease modification. This review summarizes the biological functions of BTK and critically evaluates clinical and translational evidence in chronic spontaneous urticaria (CSU), atopic dermatitis (AD), pemphigus, psoriasis, and hidradenitis suppurativa (HS). Evidence is strongest for short-term symptom control in CSU cases. Clinical value remains uncertain in pemphigus and HS, rilzabrutinib did not meet its primary AD efficacy endpoint and topical atuzabrutinib showed no exploratory efficacy benefit, and psoriasis evidence is preclinical. Priorities include prospective validation of predictive biomarkers, disease-specific confirmatory trials, agent- and setting-specific safety assessments, and long-term and real-world follow-up.

  • Open Access

    JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases

    by Bingrun Li, Xiaoting Song, Cunhao Shan, Junchen He, Zihan Wang, Katarina Stevanovic, Torsten Zuberbier, Zuotao Zhao, Litao Zhang

    The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway is involved in the pathogenesis of a variety of inflammatory and autoimmune skin diseases, such as atopic dermatitis (AD), psoriasis, alopecia areata (AA), vitiligo, etc. Many cytokines are involved in the occurrence and development of these diseases through the JAK-STAT-mediated intracellular signaling. Small molecule JAK inhibitors (JAKi) have demonstrated substantial efficacy in the treatment of many diseases, especially in inflammatory skin diseases. For example, abrocitinib and upadacitinib have been approved for the treatment of moderate-to-severe AD, and baricitinib has been approved for the treatment of severe AA. Meanwhile, clinical and preclinical studies of various JAKis for other skin diseases are ongoing. However, the traditional classification of inflammatory skin diseases according to the T helper (Th) immune axis fails to distinguish between cytokine signals that are mechanistically dependent on the JAK-STAT pathway and those that are not, thus limiting its utility for guiding targeted therapy. Accordingly, we propose a functional refinement framework that integrates JAK-dependent cytokine modules into the established Th immune axis system. This article reviews the pathogenesis of “JAK-STAT pathway-associated skin diseases” and the available efficacy evidence of JAKi therapy, aiming to improve the mechanistic understanding and rational clinical application of JAKi and provide valuable references for clinical diagnosis and treatment.


  • Open Access

    Weakly-supervised deep learning on pathological whole-slide images for cutaneous vasculitis and its mimickers: a high-performance diagnostic support tool

    by Ding Luo, Yaoxing Guo, Bingrun Li, Junchen He, Cunhao Shan, Ankang Gu, Peng Cao, Wenhua Qin, Litao Zhang

    Cutaneous vasculitis represents a heterogeneous group of disorders characterized by inflammation and necrosis of blood vessels within the skin, with or without systemic involvement. The pathological diagnosis of cutaneous vasculitis remains a significant challenge due to its pathological manifestations overlapping with various inflammatory skin diseases and the inherent subjectivity of manual diagnostic criteria. This study leveraged deep learning technology to develop a reliable diagnostic model for whole slide images (WSIs) of cutaneous vasculitis, aiming to standardize and enhance the consistency of cutaneous vasculitis pathology assessment. The study incorporated WSIs from two medical research centers between 2018 and 2024, comprising 378 WSIs of cutaneous vasculitis, 285 WSIs of edematous dermatitis, 286 WSIs of granulomatous inflammation, and 247 WSIs of panniculitis. To circumvent the substantial resource burden associated with pixel-by-pixel manual annotation of ground truth labels, this study implemented a weakly-supervised learning strategy that required only pathological diagnostic reports as labels. The results demonstrated that the deep learning-based WSI diagnostic model achieved an impressive AUC of 98.39% in multi-classification diagnostic tasks, serving as a standardized adjunct to help mitigate the variability and inconsistency inherent in manual diagnosis. Furthermore, the model can generate diagnostic predictions within milliseconds and highlight regions containing highly suspicious diagnostic evidence, significantly enhancing pathologists' work efficiency.

  • Psoriasis intervention by Huai'er (): unveiling novel targetsnetwork pharmacology.

    by L I Keyao, Shu Ye, Chang Jing, Tang Jianping, Zhang Litao, Wei Zhu

    To investigate the therapeutic effects of Huai'er (Trametes) on psoriasis by identifying specific molecular targets and pathways involved in regulating keratinocyte behavior and immune responses. Cellular experiments were conducted using human keratinocyte cell line (HaCaT) keratinocytes to evaluate the effects of Huai'er (Trametes) on cell proliferation, migration, and inflammatory factor expression. Additionally, an imiquimod (IMQ)-induced psoriasis-like mouse model was established to assess the therapeutic efficacy of Huai'er (Trametes) in vivo. Network pharmacology and transcriptomic analyses were performed to identify potential targets and pathways. Huai'er (Trametes) significantly inhibited HaCaT keratinocyte proliferation and migration in vitro, as evidenced by reduced 5-ethynyl-2'-deoxyuridine incorporation and wound healing rates. In the IMQ-induced psoriasis-like mouse model, Huai'er (Trametes) treatment reduced erythema, scaling, and dermal infiltration of inflammatory cells, demonstrating its efficacy in alleviating psoriasis symptoms. Network pharmacology and transcriptomic analyses identified signal transducer and activator of transcription 1 (STAT1) as a central target modulated by Huai'er (Trametes). This regulation was associated with decreased expression of pro-inflammatory cytokines, including interleukin-17A and tumor necrosis factor alpha, both in vitro and in vivo. This study demonstrates that Huai'er (Trametes) exerts therapeutic effects on psoriasis by modulating STAT1, thereby inhibiting keratinocyte proliferation and inflammatory responses. The findings provide a foundation for further research into the potential of Huai'er (Trametes) as a treatment for psoriasis.

  • Open Access

    Genomic Analysis Defines Increased Circulating, Leukemia-Induced Macrophages That Promote Immune Suppression in Mouse Models of FGFR1-Driven Leukemogenesis

    by Ting Zhang, Atsuko Matsunaga, Xiaocui Lu, Hui Fang, Nandini Chatterjee, Ahmad Alimadadi, Stephanie F. Mori, Xuexiu Fang, Gavin Wang, Huidong Shi, et al.

    The development of FGFR1-driven stem cell leukemia and lymphoma syndrome (SCLL) in mouse models is accompanied by an increase in highly heterogenous myeloid derived suppressor cells (MDSCs), which promote immune evasion. To dissect this heterogeneity, we used a combination of CyTOF and scRNA-Seq to define the phenotypes and genotypes of these MDSCs. CyTOF demonstrated increased levels of circulating macrophages in the peripheral blood of leukemic mice, and flow cytometry demonstrated that these macrophages were derived from Ly6CHi M-MDSC as well as the Ly6CInt and Ly6CLow monocytic populations. Consistently, scRNA-Seq analysis demonstrated the accumulation of non-classical monocytes (ncMono) during leukemia progression, which also express macrophage markers. These leukemia-induced macrophages show continuous transcriptional reprogramming during leukemia progression, with the upregulation of cellular stress response genes Hspa1a and Hspa1b and inflammation-related gene Nfkbia. Trajectory analysis revealed a transition from classical monocytes (cMono) to ncMono, and potential genes orchestrating this transition process have been identified. Furthermore, T-cell suppression assays demonstrated the immune suppressive abilities of leukemia-induced circulatory macrophages. Targeting these macrophages with the GW2580 CSF1R inhibitor leads to restored immune surveillance and improved survival. Overall, we demonstrate that circulating macrophages are responsible, at least in part, for the immune suppression in SCLL leukemia models, and targeting macrophages in this system improves the survival of leukemic mice.


  • A case of SAPHO syndrome with wrist involvement as the first presentation and response to tofacitinib therapy

    by Cunhao Shan, Fanzhang Meng, Aijie Yuan, Zhimin Lin, Fan Bu, Litao Zhang, Chen Li


  • Open Access

    Biological and target synthetic treatments for chronic spontaneous urticaria: A systematic review and network meta‐analysis

    by Zuotao Zhao, Yaqi Zheng, Xiaoting Song, Chengyue Peng, Shuanglu Liao, Peixin Zhang, Yen Tan, Xiaojie Huang, Litao Zhang

    Background: Most biological and synthetic target‐specific drugs for antihistamine‐refractory chronic spontaneous urticaria (CSU) have not been compared head‐to‐head. This systematic review and network meta‐analysis evaluated their relative efficacy and safety.Methods: Searches were conducted on PubMed, Embase, Web of Science and Cochrane library databases to March 25, 2024 for randomized trials. A random‐effects model was used to calculate the network estimates reported as mean differences (MD) and odds ratios (OR) with corresponding 95% CIs. Main outcomes included the weekly urticaria activity score (UAS7), adverse events (AEs) and serious adverse events (SAEs).Results: 23 randomized clinical trials with 6933 participants that compared 26 different interventions or dosages and placebos were included. Omalizumab 300 mg [MD −10.07, 95% CI (−11.35; −8.82)] continues to demonstrate superior efficacy compared with placebo. Remibrutinib, at doses of 35 mg once daily [MD −7.80, 95% CI (−12.76; −2.51)], 25 mg twice daily [MD −7.69, 95% CI (−9.85; −5.76)], and 10 mg twice daily [MD −7.61, 95% CI (−12.59; −2.47)], had the best overall performance for efficacy and safety. Dupilumab, fenebrutinib, and rilzabrutinib also showed greater efficacy than placebo. The results were similar for the proportion of patients who achieved UAS7 ≤ 6 or UAS7 = 0. No significant differences were found among all treatment comparisons for AEs and SAEs.Conclusion: The findings of this study indicate that the biological agent omalizumab 300 mg and the oral small molecule remibrutinib at doses of 35 mg, 25 mg, or 10 mg are recommended for patients with antihistamine‐refractory CSU.Trial Registration: PROSPERO: CRD42024516289